Results: MUC1 protein and mRNA was detectable in the majority of cases and was associated with hormone-receptorpositive status (P < 0.001). High MUC1 protein and mRNA expression were associated with lower probability of pathologic complete response (P = 0.017 and P < 0.001) and with longer patient survival (P = 0.03 and P < 0.001). In multivariable analysis, MUC1 protein and mRNA expression were independently predictive (P = 0.001 and P < 0.001). MUC1 protein and mRNA expression were independently prognostic for overall survival (P = 0.029 and P = 0.015).
Conclusions: MUC1 is frequently expressed in breast cancer and detectable on mRNA and protein level from FFPE tissue. It provides independent predictive information for therapy response and survival after neoadjuvant chemotherapy. In clinical immunotherapy trials, MUC1 expression may serve as a predictive marker. Key words: breast cancer, Mucin-1, neoadjuvant chemotherapy, pCR, prognosis introduction Mucin-1 (MUC1, epithelial membrane antigen, EMA) is a transmembrane glycoprotein that is expressed on the apical membrane of epithelial cells. It is composed of a heavily glycosylated extracellular domain and an intracellular tail. MUC1 overexpression and an abnormal pattern of glycosylation are common features of breast cancer and human epithelial cancer in general [1] .
MUC1 overexpression has been shown to promote tumor development in mouse models [2] and to fulfill several functions critical for cancer initiation and progression. Recently, a MUC1-induced gene signature was found to be associated with worse outcome in breast cancer patients [3] . With its extracellular domain, MUC1 may play a pivotal role in the immunosurveillance of cancer. Abnormal localization on nonapical membranes and abnormally glycosylated MUC1 on cancer cells can trigger a cytotoxic T-cell response [4] . The presence of autoantibodies to glycosylated MUC1 in the serum of patients with early breast cancer is associated with better outcome [5] .
Given its abundant expression in cancer cells and its experimentally well-established role in cancer biology, several approaches have been pursued for targeting MUC1 in cancer therapy. In a study of the National Cancer Institute, MUC1 was ranked as the second most promising candidate tumor antigen for the development of tumor vaccines with a high clinical potential [6] .
L-BLP25, a liposomal peptide vaccine targeting MUC1 expressing cells, has proven its activity in phase II trials in advanced nonsmall-cell lung cancer (NSCLC) [7] . Currently, two phase III trials are running in this setting (START trial, NCT00409188 and INSPIRE trial, NCT01015443). In breast cancer, a phase II study is conducted in the neoadjuvant setting by the Austrian Breast and Colorectal Cancer Study Group (ABCSG-34 trial; EudraCT number: 2011-004822-85).
With regard to these current clinical trials, the aim of this study was to evaluate the feasibility of MUC1 expression analysis as a biomarker in formalin-fixed paraffin-embedded (FFPE) samples by immunohistochemistry and quantitative RT-PCR. Further objectives were the comparison of MUC1 expression among different molecular breast cancer subtypes and the evaluation of its impact on therapy response and survival following neoadjuvant anthracycline-taxane-based chemotherapy.
patients and methods gepartrio pilot and main trials
The neoadjuvant GeparTrio pilot (NCT00544765) [8] and GeparTrio (NCT00544765) [9, 10] trials were prospective, randomized, multicenter phase II and III trials including 2357 patients with primary breast cancer (cT2-4 cN0-3 cM0). Patients were recruited between 2001 and 2005. The protocol included two initial cycles of docetaxel, adriamycin and cyclophosphamide (TAC) for all patients with subsequent evaluation of sonographic response. Responders received additional four cycles of TAC ( pilot study) or were randomly assigned to four or six additional cycles of TAC (main study). Nonresponders were randomized to receive either four additional cycles of TAC or four cycles of vinorelbine and capecitabine (NX). Positive hormone-receptor status was defined as ≥10% of tumor cells with estrogen receptor and/or progesterone receptor expression. Trastuzumab for HER2−positive cases was not available at that time. Detailed information on the studies is available in the original publications [8] [9] [10] [11] . All patients gave written informed consent for study participation and biomaterial collection; all necessary approvals by ethics committees and authorities were obtained.
immunohistochemistry for Mucin-1 FFPE pretreatment core biopsies were prospectively collected and centrally archived. Immunohistochemical staining for Mucin-1 was carried out on tissue microarrays (TMAs) according to standard procedures (1 : 200; clone MA695; Leica Biosystems Newcastle, Ltd, Newcastle Upon Tyne, UK). The stained slides were digitalized (Mirax Scan, Zeiss, Jena, Germany) and evaluated by virtual microscopy using the VMScope Slide Explorer (VMScope, Berlin, Germany) by experienced breast pathologists (SDE and CD) who were blinded to clinical outcome. The percentage of positive tumor cells (0% = 0, 1%-10% = 1, 11%-50% = 2, 51%-80% = 3, 81%-100% = 4) and the staining intensity (negative = 0, weak = 1 moderate = 2, strong = 3) were evaluated. The numeric values of both parameters were multiplied, resulting in an immunoreactivity score (IRS) ranging from 0 to 12 [12] . For statistical analysis, two groups with low or high MUC1 expression were defined based on data distribution (IRS 0-4 versus IRS 6-12). Using this cutoff, cases were defined as high for MUC1 protein when more than 50% of cells were stained with at least moderate intensity or more than 10% with strong intensity.
quantitative real-time PCR for Mucin-1 mRNA RNA was extracted from 10-μm FFPE tissue slides using a fully automated method based on silica-coated magnetic beads and a liquid-handling robot (Siemens Healthcare Diagnostics, Tarrytown, NY) [13] . Relative expression levels of Mucin-1 mRNA and the reference gene RPL37A were assessed by quantitative real-time PCR using sequence-specific primers and TaqMan 
statistical analysis
Pathologic complete response ( pCR) was defined as the absence of any invasive cancer in the breast and lymph nodes (ypT0/ypTis ypN0). Diseasefree survival was defined as time from study entry to local or distant disease relapse; overall survival was defined as the time from study entry to death from any cause.
The cutoff point for protein data was defined as described above. MUC1 mRNA data were used as a continuous variable in most calculations. For the definition of two groups of high and low MUC1 mRNA, a cutoff was chosen using an automated method to determine the best point for splitting the patients according to overall survival [14] . To evaluate associations between clinical and pathological variables including pCR rate with binominal MUC1 expression data, the χ 2 test was used. t-Tests or ANOVA was used for comparison of continuous MUC1 mRNA levels with clinical and pathological variables and logistic regression to evaluate the association of mRNA levels with pCR. Logistic regression was calculated to examine the predictive value of MUC1 protein and mRNA expression for therapy response in a multivariable model. For survival analyses, the Kaplan-Meier method with log-rank test was used. Proportional hazards regression was used for multivariable survival analyses. All P-values were computed two sided and defined as statistically significant when <0.05.
results
Pretreatment samples of 691 cases were evaluable by immunohistochemistry on the TMA. Tissue from 286 cases was used for RNA extraction and qRT-PCR for MUC1 mRNA. Clinical and biomarker characteristics are given in Table 1 . MUC1 immunostainig was detactable in the majority of cases, 5% were negative for MUC1. Cytoplasmic (35%) or cytoplasmic and membranous (56%) staining were the most frequently observed patterns. In 4% of cases, apical membranes were stained (Figure 1 ). 211 cases (30%) were defined as low for MUC1, 480 (70%) as high for MUC1 protein expression. MUC1 mRNA expression levels (20 -ΔCT units) ranged from 12.5 to 22.5, covering a dynamic range of three orders of magnitude. MUC1 mRNA levels were higher in cases defined as high for MUC1 protein expression (mean 20 -ΔCT value 18.8 versus 17.2; P < 0.001). The cutoff point for the dichotomous analysis of mRNA data was chosen as > 17.92 (20 -ΔCT value), resulting in 178 cases (62.2%) with high MUC1 expression and 108 cases (37.8%) with low MUC1 expression.
MUC1 is associated with positive prognostic factors. Figure 2A illustrates the association of MUC1 mRNA expression with clinical and biomarker characteristics. Mean MUC1 mRNA expression level was higher in HR+ cases (P < 0.001), in low-grade tumors (P < 0.001), in lobular breast cancer (P = 0.033) and in patients ≥ 50 years of age (P = 0.036). High MUC1 protein expression was associated with HR+ tumors (P < 0.001), low-grade tumors (P < 0.001) and lobular histology (P = 0.027). In HR−/HER2− tumors, the lowest levels of MUC1 mRNA (P < 0.001; Figure 2B ) and protein (P < 0.001; Figure 2C ) expression were observed compared with other subtypes.
High MUC1 mRNA (P < 0.001) and protein expression (P = 0.017) were associated with a lower probability of achieving pCR after neoadjuvant chemotherapy (Figure 3 ). The pCR rates were 30% versus 15% for tumors with low versus high MUC1 protein expression and 35% versus 12% for tumors with low versus high MUC1 mRNA, respectively. In stratified analysis, MUC1 mRNA and protein expression were associated with a lower probability of pCR in HR+ (P < 0.001), HER2− (P < 0.001 and P = 0.012) and HR+/HER2− (P < 0.001) cases (Figure 3) . Low MUC1 mRNA, but not protein expression, was also predictive in HR−/HER2− cases (P = 0.034). Both high MUC1 mRNA and high protein expression were independent predictive markers for a lower probability of achieving a pCR (Table 2 ). In multivariable logistic regression including standard clinical and biomarker characteristics ( patient age, tumor stage, nodal status, tumor histology, tumor grade, HR and HER2 status) and MUC1 mRNA expression, MUC1 (P < 0.001) and HER2 status (P = 0.002) were independently predictive for pCR. When MUC1 protein data were included in the model, MUC1 (P = 0.001), patient age (P = 0.002), HR status (P < 0.001), HER2 status (P = 0.002) were independent markers (Table 2) .
High MUC1 mRNA (P = 0.018), but not protein (P = 0.182) expression was predictive for increased disease-free survival compared with low MUC1 expression in the overall study population ( Figure 3E and H) . Concerning overall survival, both mRNA and protein expression were prognostic (P < 0.001 and P = 0.031) for longer patient survival ( Figure 3F and I) . In stratified analyses, MUC1 mRNA expression was prognostic for disease-free and overall survival in HR+ (P = 0.007 and P = 0.001), HER2− (P = 0.003 and P < 0.001) and HR+/HER2− tumors (P = 0.001 and P = 0.001; Figure 3B ). MUC1 protein expression was prognostic for overall survival in the subgroup of HER2− cases (P = 0.005).
We further evaluated if the subcellular distribution of MUC1 staining is associated with clinical outcome. When staining patterns were compared, tumors negative for MUC1 were associated with shorter disease-free survival (P = 0.008) compared with all other staining patterns. For overall survival, Both high MUC1 mRNA and high protein expression were independently prognostic markers for overall survival in multivariable proportional hazards regression including patient age, tumor stage, nodal status, tumor histology, tumor grade, HR and HER2 status (Table 3) . When MUC1 mRNA was included in the model, MUC1 (P = 0.005) was independently prognostic for overall survival. In a model including MUC1 protein expression, MUC1 (P = 0.029) and HR status (P = 0.049) retained their prognostic impact on patient survival.
discussion
The role of MUC1 as an oncogene is experimentally established [15] . Overexpression of MUC1 promotes breast cancer development [2] and overexpression of its intracellular domain leads to mammary gland hyperplasia in mouse models [16] . Several in vitro studies have shown the role of MUC1 in influencing cellular processes like regulation of cell polarity, transcriptional control, inhibition of apoptosis and blocking of death-signals by interaction with intracellular signaling pathways like β-Catenin, EGFR, Wnt and NFκB signaling [1, 17] . A MUC1-induced gene signature established in a mouse xenograft model, is associated with worse patient outcome in breast cancer [3] .
Since its initial description as a protein aberrantly expressed in breast cancer in 1984 [18] , several studies have evaluated the expression of MUC1 in healthy breast tissue and breast cancer [17, 19, 20] . In contrast to the experimental data, in most translational studies, high MUC1 expression was associated with improved patient survival, possibly due to its association with lower tumor grade and estrogen receptor positivity. Our results are consistent with those previous evaluations of MUC-1 as a good prognostic factor. High MUC1 expression was associated with longer patient survival in the overall study group as well as in the subgroups of HR+, HER2− and HR+/HER2− cases. Some studies reported that the subcellular distribution of MUC1 is associated with clinical outcome with a favorable prognosis when MUC1 is restricted to the apical membrane. We did not make this observation in our study. It might be that an apical expression of is a surrogate for tumor grade, as poorly differentiated tumors often exhibit a nonpolarized growth pattern without definable apical membranes. This could explain the positive prognostic outcome observed in some studies, and it can also explain the low number of cases with apical expression in our neoadjuvant cohort. This cohort has been 
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selected to contain more aggressive tumors, and only 8% are grade 1. In addition to the prognostic effect, we show that MUC1 is also a predictive factor in the neoadjuvant setting and that both mRNA and protein levels could be used as biomarker. High MUC1 expression was associated with a lower probability of achieving pCR following neoadjuvant anthracycline-taxane-based chemotherapy not only in the overall study group, but also among HR+, HER2− and HR +/HER2− cases and in multivariable logistic regression in the overall study group.
The strengths of our investigations are that we used a cohort from a large neoadjuvant trial with defined therapy as well as predefined response and outcome data. A limitation of this biomarker study is the incomplete tissue availability from the initial trial population. However, the clinicopathological characteristics of the biomarker subcohort are comparable to the entire study population. Another limitation might be that we used only one antibody to detect MUC1 by immunohistochemistry. The clone MA695 binds to a carbohydrate epitope, detecting the glycosylated form of MUC1. A systematical comparison of MUC1 antibodies has been published [21] . We decided to use this antibody because MUC1 has been shown to be heavily and abnormally glycosylated in breast cancer and this feature is likely to contribute to its role in tumor biology and tumor-/host interactions.
It is suggestive that the association of MUC1 with worse therapy response but better patient outcome may be due to its association with estrogen receptor expression and low nuclear grade. However, MUC1 expression yields additional information as it is a significant marker for therapy response and survival in multivariable analyses.
A recent pooled analysis of more than 6000 patients revealed that response after neoadjuvant chemotherapy serves as a surrogate for patient survival in TNBC, HER2+ (nonluminal) and luminal B (HER2−) tumors [22] . The "triple-negative paradox" refers to the phenomenon that triple-negative breast cancer is generally associated with higher pCR rates but shorter patient survival [23] . This has been attributed to the benefit from endocrine therapy in hormone-receptor-positive breast cancer and the higher risk of relapse in patients with triplenegative disease that do not achieve pCR. Accordingly, it is often observed that favorable prognostic markers are associated with decreased response to chemotherapy and vice versa.
A possible explanation of our results might be the role of MUC1 in cancer immunosurveillance. Immunologic processes are believed to influence efficacy of conventional chemotherapy [24] . Recently, we have shown that tumor-associated lymphocytes are an independent predictor of response to neoadjuvant chemotherapy in breast cancer [25] . Aberrantly glycosylated MUC1 epitopes have been shown to elicit a cytotoxic T-cell response [26] and the presence of MUC1 antibodies in the serum of breast cancer patients is associated with a favorable prognosis [5] . Our results may reflect the role of MUC1 in inducing an immunologic response that possibly evolves its full potential under the influence of chemotherapy. Interestingly, pCR would not be a necessary surrogate for survival in this model, because the effect could be explained by more subtle long-term immunologic adaptations than the reduction of tumor mass that is reflected by pCR. Given the high frequency of MUC1 overexpression, several approaches have been developed to take advantage of MUC1 as a therapeutic target in breast and other human cancers. In a 'prioritization' study of cancer antigens, MUC1 was ranked on place two on a list of antigens with the highest potential for the development of cancer vaccines among 75 candidates [6] .
L-BLP25 has been shown to increase patient survival in a phase II study in nonsmall-cell lung cancer (NSCLC) [7] . Phase III trials have been initiated in this setting (START trial, NCT00409188 and INSPIRE trial, NCT01015443). In breast cancer, a phase II study is conducted in the neoadjuvant setting by the Austrian Breast and Colorectal Cancer Study Group (ABCSG-34 trial). Two other tumor vaccines targeting MUC1 have been developed that are currently tested in clinical trials [27, 28] . Antibodies targeting MUC1 have had limited success so far, maybe due to the presence of circulating MUC1 in patient serum. A phase II trial testing the MUC1 antibody AS1402 with letrozole in hormone-receptor-positive advanced or metastatic breast cancer was stopped early because of a trend toward worse response [29] . Alternative approaches are direct targeting of MUC1 with synthetic inhibitors [30] or antibodies targeting both the intra-and extracellular portion of MUC1 [31] . Recently, a MUC1 aptamer carrying doxorubicin has been described [32] for the targeted delivery of cytotoxic drugs to cancer cells.
The primary aim of this study was to provide a systematical evaluation of MUC1 expression among different breast cancer subtypes in the light of ongoing immunotherapeutic trials. The described methods for MUC1 determination could be used for prediction of response when MUC1 is therapeutically targeted. We further demonstrate that MUC1 is associated with distinct clinical behavior, and that it adds independent prognostic information that is not explained by its association with ER+ tumors. The data support the hypothesis that MUC1 is a relevant target in breast cancer and that anti-MUC1 strategies could be a promising approach, especially for large, HR+ tumors where treatment options are limited to date.
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